CureVac Review, Focusing on 2nd-Gen COVID Vaccine
Analysts at Berenberg Bank provided their outlook on CureVac N.V. (NASDAQ:CVAC), mentioning that they believe the withdrawal of first-generation CVnCoV from the approval process effectively removes an overhang from the stock.
According to the analysts, they like the potential of the GlaxoSmithKline (GSK) partnered second-generation COVID-19 vaccine (CV2CoV) and believe it has the potential to capture what they expect will be an active booster market given the virus likely continues to mutate; the emergence of the omicron variant being a prime example of this.
| Symbol | Price | %chg |
|---|---|---|
| 207940.KS | 915000 | 0 |
| 068270.KS | 200000 | 0 |
| 196170.KQ | 283500 | 0 |
| 028300.KQ | 79200 | 0 |
CVAC Ratings Summary
CVAC Quant Ranking
Related Analysis
